Company profile

Richard A. Gonzalez
Incorporated in
Fiscal year end
IRS number

ABBV stock data

FINRA relative short interest over last month (20 trading days) ?

Investment data

Data from SEC filings
Securities sold
Number of investors


21 Feb 20
25 Feb 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Dec 19 Sep 19 Jun 19 Mar 19
Revenue 8.7B 8.48B 8.26B 7.83B
Net income 2.8B 1.88B 741M 2.46B
Diluted EPS 1.88 1.26 0.49 1.65
Net profit margin 32.18% 22.22% 8.98% 31.37%
Operating income 3.96B 2.62B 3.4B 3.01B
Net change in cash 29.28B 5.48B 275M -2.39B
Cash on hand 39.92B 10.65B 5.17B 4.9B
Cost of revenue 2.01B 1.92B 1.82B 1.69B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 33.27B 32.75B 28.22B 25.64B
Net income 7.88B 5.69B 5.31B 5.95B
Diluted EPS 5.28 3.66 3.3 3.63
Net profit margin 23.69% 17.36% 18.82% 23.22%
Operating income 12.98B 6.38B 9.55B 9.34B
Net change in cash 32.64B -2.01B 4.2B -3.3B
Cash on hand 39.92B 7.29B 9.3B 5.1B
Cost of revenue 7.44B 7.72B 7.04B 5.83B

Financial data from AbbVie earnings reports

70.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2058 1884 +9.2%
Opened positions 282 135 +108.9%
Closed positions 108 138 -21.7%
Increased positions 777 801 -3.0%
Reduced positions 759 734 +3.4%
13F shares
Current Prev Q Change
Total value 95.09B 78.59B +21.0%
Total shares 1.05B 1.04B +0.9%
Total puts 22.2M 19.78M +12.3%
Total calls 19.3M 18.96M +1.8%
Total put/call ratio 1.2 1.0 +10.3%
Largest owners
Shares Value Change
Vanguard 122.57M $10.85B +0.7%
BLK BlackRock 98.59M $8.73B -3.0%
Capital Research Global Investors 86.6M $7.67B -13.9%
STT State Street 68.82M $6.09B +0.1%
FMR 40.24M $3.56B +7.8%
N Price T Rowe Associates 28.09M $2.49B +42.0%
Geode Capital Management 24.43M $2.16B +2.9%
NTRS Northern Trust 19.45M $1.72B -0.9%
JPM JPMorgan Chase & Co. 17.95M $1.59B +33.7%
Orbis Allan Gray 16.1M $1.43B -6.5%
Largest transactions
Shares Bought/sold Change
Capital Research Global Investors 86.6M -14.01M -13.9%
N Price T Rowe Associates 28.09M +8.31M +42.0%
Capital World Investors 0 -7.6M EXIT
JPM JPMorgan Chase & Co. 17.95M +4.53M +33.7%
Renaissance Technologies 11.8M +4.49M +61.5%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 4.06M +3.46M +580.6%
TFC Truist Financial 3.76M +3.29M +693.2%
BLK BlackRock 98.59M -3.05M -3.0%
FMR 40.24M +2.93M +7.8%
Nuveen Asset Management 13.04M +2.59M +24.8%

Financial report summary

  • The expiration or loss of patent protection and licenses may adversely affect AbbVie's future revenues and operating earnings.
  • AbbVie's major products could lose patent protection earlier than expected, which could adversely affect AbbVie's future revenues and operating earnings.
  • AbbVie's research and development efforts may not succeed in developing and marketing commercially successful products and technologies, which may cause its revenues and profitability to decline.
  • AbbVie's biologic products are subject to competition from biosimilars.
  • Significant safety or efficacy issues could arise for AbbVie's products, which could have a material adverse effect on AbbVie's revenues and financial condition.
  • AbbVie is subject to numerous governmental regulations, and it can be costly to comply with these regulations and to develop compliant products and processes.
  • AbbVie is dependent on wholesale distributors for distribution of its products in the United States and, accordingly, its results of operations could be adversely affected if they encounter financial difficulties.
  • AbbVie has debt obligations that could adversely affect its business and its ability to meet its obligations.
  • Failure to attract and retain highly qualified personnel could affect AbbVie’s ability to successfully develop and commercialize products.
  • The pending acquisition of Allergan may not be completed on the currently contemplated timeline or terms, or at all, and may not achieve the intended benefits.
  • The indebtedness of the combined company following the consummation of the Acquisition will be substantially greater than AbbVie’s indebtedness on a standalone basis and greater than the combined indebtedness of AbbVie and Allergan prior to the announcement of the acquisition. This increased level of indebtedness could adversely affect the combined company’s business flexibility and increase its borrowing costs.
Management Discussion
  • AbbVie's strategy has focused on delivering strong financial results, advancing and investing in its pipeline and returning value to shareholders while ensuring a strong, sustainable growth business over the long term. The company's financial performance in 2019 included delivering worldwide net revenues of $33.3 billion, operating earnings of $13.0 billion, diluted earnings per share of $5.28 and cash flows from operations of $13.3 billion. Worldwide net revenues grew by 3% on a constant currency basis, primarily driven by revenue growth related to IMBRUVICA and VENCLEXTA as well as the continued strength of HUMIRA in the U.S. and newly launched immunology assets SKYRIZI and RINVOQ, offset by international HUMIRA biosimilar competition.
Content analysis ?
H.S. freshman Bad
New words: abnormality, accretion, accuracy, Allergan, Alvogen, ankylosing, Aptinyx, axial, bardoxolone, BBB, BELLINI, biomarker, bleeding, brazikumab, Brook, Canadian, CANOVA, Centre, certified, contradicted, coordinated, corroborated, corroboration, corroborative, device, dispute, diverse, divest, divestiture, entirety, erythrodermic, estate, eye, Fe, Florence, Foundation, Founder, futility, Genome, germline, giant, GOG, GT, heavy, Hudson, implicit, inclusive, indenture, indirect, intraperiod, Irish, JAK, jeopardize, King, leader, lifted, light, lock, McGill, menstrual, MERU, methyl, mg, MM, NaN, Natco, notch, omaveloxolone, Ontario, palsy, pangenotypic, philanthropic, phototherapy, Pine, proportion, protocol, PsA, pustular, Quebec, radiation, ratio, Reata, regenerative, requisite, RINVOQ, Santa, shorten, SKYRIZI, slightly, solicited, specialist, standalone, Sublease, subunit, sum, supranuclear, surgical, tablet, temporarily, tiered, timeframe, timeline, tranche, translocation, trustee, University, unpaid, VELIA, verified, week
Removed: accelerate, adding, antiretroviral, appellate, ASR, bear, bidder, bolivar, Chase, chemoimmunotherapy, collectability, Complementaria, complexity, consulting, contraction, core, Crohn, cycle, deductible, depict, description, devaluation, DICOM, diversified, Divisa, drew, economy, establishment, existed, forma, Fournier, gained, hyperinflationary, identifiable, improving, Industrie, investee, jury, landscape, liquidated, Louisiana, main, monoclonal, ninety, norvir, official, operational, preliminary, prepaid, principle, pro, proceeding, projection, refractory, registrational, reimburse, reinstatement, relapsed, relapsing, resolve, retrospectively, revalue, RSA, Sante, select, settle, shareholder, solid, Subtopic, taxability, technique, TriCor, tumor, twelve, unacceptably, unamortized, unaudited, undistributed, variation, VEF, Venezuela, Venezuelan, verdict, vi, voluntary, William